The science and research behind psychedelics, including their potential therapeutic uses.
In the mid-1980s, America was deeply entrenched in its War on Drugs. The media was saturated with sensationalized headlines about the dangers of drug use and trade. One such article, titled “The Losing War Against ‘Designer Drugs’,” was featured in the June 24th, 1985 issue of Business Week. The article discussed the cat-and-mouse game of …
The War on Drugs: A Look Back and the Path Forward with MAPS Read More »
New research published in iScience provides unique insights into how psilocybin alters brain activity during psychedelic experiences. The findings suggest that while the overall activity of the brain becomes more chaotic during the psychedelic state, the brain’s ability to maintain complex interactions in response to external stimulation is not affected. Psilocybin is a naturally occurring …
SAN JOSE, Calif., April 5, 2023—MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced positive topline results from an observational follow-up study evaluating the long-term safety and efficacy of MDMA-assisted therapy for post–traumatic stress disorder (“PTSD”). Preliminary findings show that participants in this study demonstrated a …
Positive Follow-Up Study on MDMA-Assisted Therapy for Treatment of PTSD Read More »
Matthew W. Johnson, Ph.D. is the Susan Hill Ward Professor in Psychedelics and Consciousness and Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. Psychedelic research is enjoying a renaissance. Recent studies have shown that psychedelic drugs like LSD and psilocybin seem to be a safe and effective method for treating conditions like depression, anxiety, …
The “heroic dose” of psychedelics, according to Johns Hopkins | Dr. Matthew Johnson Read More »
Summary: Recent studies have explored the use of psychedelics for the treatment of a range of mental health disorders. A new study reveals more insightful and mystical “trips” while exposed to psychedelics may be linked to an enduring reduction of symptoms for those with anxiety and depression. Source: Ohio State University A more mystical and …
Mystical and Insightful Psychedelic Experience May Improve Mental Health Read More »
Pharmacy Times interviewed Jordan Sloshower, MD, MSc, a clinical instructor of psychiatry at the Yale Department of Psychiatry, a member of Chacruna’s Council for the Protection of Sacred Plants, a clinical investigator in MAPS’ Expanded Access Program, a trainer with Usona Institute, co-director of West Rock Wellness, PLLC, and a member of the Board of …
Blinding in Clinical Trials Investigating Psychedelic Medicine Remains Difficult Read More »
Roland Griffiths & David Yaden || An Ode to Joy Scott Barry Kaufman is a cognitive scientist and humanistic psychologist exploring the mind, creativity, and the depths of human potential. He is a professor at Columbia University and founder and director of the Center for Human Potential. Dr. Kaufman has taught at Columbia University, Yale, …
The Scientific Psychedelics Revolution and Embracing Mortality Read More »
“It’s almost as if people are seeing with their eyes closed.” Taking DMT is a bit like putting your brain through a jet engine and getting your consciousness blown out the other side. There’s no “you” anymore. You’re just kind of everywhere, surrounded by colours and fractals and aliens that look a bit like elves. …
Scientists Have a Fascinating New Map of the Human Brain on DMT Read More »
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial The nonprofit Multidisciplinary Association for Psychedelic Studies’ (MAPS) clinical research program has achieved an important milestone: a successful confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD). The clinical research program that began in 1992 has been sponsored by the nonprofit MAPS …
